Area of Science:

• Nephrology
• Dermatology
• Pharmacology

Background:

• Chronic Kidney Disease associated Pruritus (CKD-aP) is a prevalent and burdensome complication in patients with chronic kidney disease (CKD), particularly those undergoing dialysis.
• The exact pathophysiology of CKD-aP is not fully understood, and current research is limited, making effective management a significant clinical challenge.
• Existing treatment options for CKD-aP offer limited clinical benefits, highlighting the need for novel therapeutic strategies.

Approach:

• This review synthesizes available literature on CKD-aP treatments.
• It critically evaluates the clinical efficacy and limitations of current pharmacological interventions.
• The review specifically examines the role of opioid receptors, particularly kappa opioid receptors, in the pathophysiology of CKD-aP.

Key Points:

• Opioid receptors, especially the kappa opioid receptor (KOR), are implicated in the complex pathophysiology of CKD-aP.
• Kappa opioid receptor agonists represent a promising therapeutic avenue for managing CKD-aP.
• Further research is needed to fully elucidate the mechanisms and optimize treatments for CKD-aP.

Conclusions:

• Current treatments for CKD-aP are insufficient, underscoring the need for improved therapeutic approaches.
• Targeting the kappa opioid receptor system offers a potential pathway for developing more effective treatments for pruritus in CKD patients.
• Understanding the role of opioid receptors is crucial for advancing the management of CKD-aP.